Reuters: Spending and board oversight irk some Elan investors

[chris]

Spending and board oversight irk some Elan investors
      

BOSTON (Reuters) - It's not just a slowing growth of its main product and an 80 percent stock decline in five months that has some big investors in Irish drugmaker Elan  riled up.<div class="feedflare">
You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login
</div><img src="You are not allowed to view links. Register or Login" height="1" width="1"/>
      

You are not allowed to view links. Register or Login